BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260727T152941EDT-3591daiti0@132.216.98.100
DTSTAMP:20260727T192941Z
DESCRIPTION:Laurent Azoulay\, PhD\n\nAssociate-Professor – Department of On
 cology\n	Associate-Member – Department of EBOH\n	Faculty of Medicine\, McGil
 l University\n	Investigator\, Centre for Clinical Epidemiology\, LDI-JGH\n
 \nPioglitazone and the risk of bladder cancer: An ongoing saga\n\nALL ARE 
 WELCOME\n\nAbstract:\n\nPioglitazone is an antidiabetic drug that has been
  shown to improve glycemic levels in patients with type 2 diabetes. Howeve
 r\, its safety is controversial\, with earlier studies associating its use
  with an increased risk of bladder cancer. While the findings of these stu
 dies led to a black-box warning on the drug’s label\, recent studies with 
 longer follow-up have failed to observe an association\; but these had imp
 ortant methodological shortcomings. In this seminar\, I will present the f
 indings of a large population-based study that used a robust pharmacoepide
 miologic approach to address different sources of bias. This study fits wi
 thin a broader research program in cancer pharmacoepidemiology.\n\nObjecti
 ves:\n\n\n	To review the role of pharmacotherapies in the management of typ
 e 2 diabetes\n	To review the controversies associating pioglitazone with bl
 adder cancer\n	To acquire new knowledge of the possible association between
  pioglitazone and bladder cancer\n\n\nBio:\n\nDr. Laurent Azoulay is an As
 sociate Professor in the Department of Oncology\, McGill University. He re
 ceived his PhD in 2007 from the Université de Montréal\, and then joined M
 cGill University in 2009. His research interests are primarily in cancer p
 harmacoepidemiology. He has conducted numerous studies assessing the assoc
 iation between commonly prescribed drugs and cancer incidence\, as well as
  evaluating the short- and long-term safety of cancer treatments. His rese
 arch program is funded by a CIHR Foundation Scheme grant.\n\nhttp://www.me
 dicine.mcgill.ca/oncology/fac/facandstaff_show.asp?Oncology...\n
DTSTART:20160222T210000Z
DTEND:20160222T220000Z
LOCATION:Room 521\, McIntyre Medical Building\, CA\, QC\, Montreal\, H3G 1Y
 6\, 3655 promenade Sir William Osler
SUMMARY:Special Epidemiology Seminar: 'Pioglitazone and the risk of bladder
  cancer: An ongoing saga'
URL:https://www.mcgill.ca/epi-biostat-occh/channels/event/special-epidemiol
 ogy-seminar-pioglitazone-and-risk-bladder-cancer-ongoing-saga-258504
END:VEVENT
END:VCALENDAR